SCHEMBL258027

SCHEMBL258027

O=C(c1ccc(B(O)O)cc1)N1CCCCC1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 8/20 0.74
ALDH1A1 P00352 3/20 0.74
LMNA P02545 1/20 0.58
KMT2A Q03164 2/20 0.57
MEN1 O00255 1/20 0.57
TSHR P16473 1/20 0.57
MAPK1 P28482 1/20 0.56
CA12 O43570 2/20 0.56
CA1 P00915 2/20 0.56
CA2 P00918 2/20 0.56
CA7 P43166 2/20 0.56
CA9 Q16790 2/20 0.56
CA14 Q9ULX7 2/20 0.56
MLYCD O95822 2/20 0.54
USP2 O75604 1/20 0.54
MAPT P10636 1/20 0.54
MBTD1 Q05BQ5 3/20 0.53
L3MBTL3 Q96JM7 3/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
MAOA P21397 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL204078 0.98 HPGD (0.70) HPGDALDH1A1LMNAKMT2AMEN1
SCHEMBL950365 0.94 HPGD (0.64) HPGDALDH1A1LMNAKMT2AMEN1
SCHEMBL29950978 0.90 HPGD (0.57) HPGDALDH1A1LMNAKMT2AMEN1
SCHEMBL28890427 0.89 HPGD (0.58) HPGDALDH1A1LMNAKMT2AMEN1
SCHEMBL7132525 0.86 HPGD (1.00) HPGDALDH1A1LMNAKMT2AMEN1
SCHEMBL27479149 0.86 HPGD (1.00) HPGDALDH1A1LMNAKMT2AMEN1
SCHEMBL10721733 0.84 HPGD (0.95) HPGDALDH1A1LMNAKMT2AMEN1
SCHEMBL109091 0.82 PHGDH (0.65) HPGDALDH1A1KMT2ATSHRMAPK1
SCHEMBL532147 0.82 POLB (0.65) HPGDLMNAKMT2AMEN1TSHR
SCHEMBL1951522 0.82 SIGMAR1 (0.64) HPGDALDH1A1L3MBTL3L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119674208-A PEO-PAN-based polymer electrolyte membrane and preparation method and application thereof 山东创鲁先进电池科技有限公司 2025-03-21 CN claimed
WO-2024016826-A1 6-POSITION SUBSTITUTED DIHYDROBENZO[E][1,2,3]OXATHIAZINE 2,2-DIOXIDE COMPOUND, PREPARATION THEREFOR, AND USE THEREOF 杭州市第七人民医院 2024-01-25 WO claimed
CN-115232090-A 6-substituted dihydrobenzo [ e ] [1,2,3] oxathiazine 2,2-dioxide compound and preparation and application thereof 杭州市第七人民医院 2022-10-25 CN claimed
CN-119674208-A PEO-PAN-based polymer electrolyte membrane and preparation method and application thereof 山东创鲁先进电池科技有限公司 2025-03-21 CN disclosed
CN-115232090-B 6-Substituted dihydrobenzo [ e ] [1,2,3] oxathiazine 2, 2-dioxide compound and preparation and application thereof 杭州市第七人民医院 2024-11-19 CN disclosed
WO-2024016826-A1 6-POSITION SUBSTITUTED DIHYDROBENZO[E][1,2,3]OXATHIAZINE 2,2-DIOXIDE COMPOUND, PREPARATION THEREFOR, AND USE THEREOF 杭州市第七人民医院 2024-01-25 WO disclosed
US-20220396581-A1 COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS Janssen Biopharma, Inc. (US) 2022-12-15 US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
CN-115232090-A 6-substituted dihydrobenzo [ e ] [1,2,3] oxathiazine 2,2-dioxide compound and preparation and application thereof 杭州市第七人民医院 2022-10-25 CN disclosed
US-11014935-B2 Compounds for the treatment of paramyxovirus viral infections Janssen Biopharma, Inc. (US) 2021-05-25 US disclosed
US-10859585-B2 Lipid probes and uses thereof THE SCRIPPS RESEARCH INSTITUTE (US) 2020-12-08 US disclosed
US-20090099131-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY DISCOVERY, INC. (US) 2009-04-16 US disclosed
US-20090099131-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY DISCOVERY, INC. (US) 2009-04-16 US disclosed
US-7494994-B2 Phenylpyridylpiperazine compounds LES LABORATOIRES SERVIER (FR) 2009-02-24 US disclosed
EP-1979353-A2 FUSED HETEROBICYCLIC KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2008-10-15 EP disclosed
WO-2008063300-A2 BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2008-05-29 WO disclosed
US-20070208053-A1 Fused heterobicyclic kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-09-06 US disclosed
WO-2007084667-A2 FUSED HETEROBICYCLIC KINASE INHIBITORS OSI PHARMACEUTICAL, INC. (US) 2007-07-26 WO disclosed
US-20060258670-A1 New phenylpyridylpiperazine compounds LES LABORATOIRES SERVIER (FR) 2006-11-16 US disclosed
WO-2006048331-A1 11β-HSD1 INHIBITORS EVOTEC AG (DE) 2006-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258670-A1 New phenylpyridylpiperazine compounds HRH4, HRH3, HRH2 HPGD 1922/4885ALDH1A1 3223/4885LMNA 4719/4885
US-20220396581-A1 COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS MAVS, SARS1, ZC3HAV1 HPGD 2844/4885ALDH1A1 3714/4885LMNA 2835/4885
US-11014935-B2 Compounds for the treatment of paramyxovirus viral infections MAVS, SARS1, ZC3HAV1 HPGD 2844/4885ALDH1A1 3714/4885LMNA 2835/4885
US-20090099131-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 HPGD 211/4885ALDH1A1 444/4885LMNA 3682/4885
US-20070208053-A1 Fused heterobicyclic kinase inhibitors MAP2K5, MAP2K7, MAP2K2 HPGD 3305/4885ALDH1A1 4769/4885LMNA 3267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.